INBRX-106 Shows Encouraging Early Data but Thesis Remains Tied to Ozekibart BLA

What happened

Interim Phase 2 data for INBRX-106 in first-line HNSCC showed a doubling of confirmed objective response rate to 44% when combined with pembrolizumab versus 21.4% with pembrolizumab alone, with deeper tumor reductions and three complete responses. However, the dataset remains early and from a limited number of patients, consistent with management's prior guidance that mature data will not be available until the second half of 2026. The DeepValue master report already characterized INBRX-106 as optionality that is not yet interpretable, and this interim read does not change that assessment. The core investment thesis continues to hinge on the ozekibart BLA submission planned for Q2 2026, which carries material regulatory risk due to a history of hepatotoxicity. Therefore, the stock's valuation remains driven by ozekibart progress rather than early INBRX-106 signals, and the WAIT rating is maintained.

Implication

While the 22.6% absolute improvement in cORR versus pembrolizumab alone is noteworthy, the small sample size and early follow-up limit its de-risking value. Investors should not overweight this readout as it remains consonant with management's 'not interpretable yet' stance. The primary catalyst—ozekibart BLA submission by end of June 2026—still faces hepatotoxicity scrutiny from the FDA. Any positive sentiment from this update provides an opportunity to trim into strength given the single-catalyst concentration and pending regulatory hurdles. The attractive entry remains near $60, and we await a concrete filing-readiness signal before upgrading.

Thesis delta

No material shift from the WAIT thesis. The INBRX-106 interim data are positive but immature, consistent with prior guidance that interpretable data will not be available until 2H 2026. The binding constraint remains the ozekibart BLA filing, and the market should not reprice the stock on early INBRX-106 signals alone.